Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336691688> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2336691688 abstract "ABSTRACT Aim: To investigate the prognostic and predictive value of the inflammatory index Neutrophil/Lymphocyte ratio (NLR) in two homogeneous groups of chemotherapy-naive metastatic pancreatic adenocarcinoma (PA) pts treated with either gemcitabine (GEM) or GEM + oxaliplatin (GEMOXA). Methods: Consecutive PA pts (n = 103, male:female = 53:50) treated at a single center with either GEM (n = 45) or GEMOXA (n = 58), mainly according to patient preference or pre-existent diabetic neuropathy, were included between April'08- October'12. Exclusion criteria were treatment with steroids or active infection. NLR was assessed before and during therapy and correlated with outcome together with common clinical and biochemical variables. Results: Among 17 analyzed variables NLR, Karhofsky Perfomance Status (KPS), d-dimer and erythrocyte sedimentation rate were found to be significantly associated with median Overall Survival (mOS) at the univariate analysis. Only NLR and KPS were independent prognosticator at multivariate analysis, with NLR displaying the highest statistical significance (Exp(b) = 1.09, p 0.01, meaning 9% increase in the risk of death for 1-unit increase in NLR). GEMOXA was associated with longer mOS, but this was not statistically significant (8 v 5.8 months (mo), p 0.07). NLR was also predictive of oxaliplatin activity, as only pts with NLR > 2.5 (cutoff determined upon ROC analysis) derived benefit from GEMOXA over GEM (mOS 9.7 v 3.9 mo, respectively, in pts with NLR > 2.5, p 0.005 and 11.7 vs 11.8 mo, respectively, in pts with NLR 2.5 who reported a NLR 2.5 (7.7 v 5.0 mo, p 0.003). Conclusions: We were able to confirm the independent prognostic value of NLR for metastatic PA pts treated with gemcitabine-based first-line chemotherapy. NLR had also a predictive value in that only pts with high NLR (worse outcome) seem to benefit from the addition of oxaliplatin. NLR and KPS may help select pts for whom a particularly poor prognosis might justify more intensive, yet less tolerable, combination regimens. Disclosure: All authors have declared no conflicts of interest." @default.
- W2336691688 created "2016-06-24" @default.
- W2336691688 creator A5004112514 @default.
- W2336691688 creator A5008060231 @default.
- W2336691688 creator A5030351372 @default.
- W2336691688 creator A5037604705 @default.
- W2336691688 creator A5041185139 @default.
- W2336691688 creator A5072842070 @default.
- W2336691688 creator A5082961127 @default.
- W2336691688 creator A5087184743 @default.
- W2336691688 date "2014-09-01" @default.
- W2336691688 modified "2023-09-27" @default.
- W2336691688 title "Predictive Role of Neutrophil/Lymphocyte Ratio (Nlr) for Oxaliplatin Efficacy in Metastatic Pancreatic Cancer Patients (Pts)" @default.
- W2336691688 doi "https://doi.org/10.1093/annonc/mdu334.101" @default.
- W2336691688 hasPublicationYear "2014" @default.
- W2336691688 type Work @default.
- W2336691688 sameAs 2336691688 @default.
- W2336691688 citedByCount "0" @default.
- W2336691688 crossrefType "journal-article" @default.
- W2336691688 hasAuthorship W2336691688A5004112514 @default.
- W2336691688 hasAuthorship W2336691688A5008060231 @default.
- W2336691688 hasAuthorship W2336691688A5030351372 @default.
- W2336691688 hasAuthorship W2336691688A5037604705 @default.
- W2336691688 hasAuthorship W2336691688A5041185139 @default.
- W2336691688 hasAuthorship W2336691688A5072842070 @default.
- W2336691688 hasAuthorship W2336691688A5082961127 @default.
- W2336691688 hasAuthorship W2336691688A5087184743 @default.
- W2336691688 hasBestOaLocation W23366916881 @default.
- W2336691688 hasConcept C121608353 @default.
- W2336691688 hasConcept C126322002 @default.
- W2336691688 hasConcept C143998085 @default.
- W2336691688 hasConcept C144301174 @default.
- W2336691688 hasConcept C2776694085 @default.
- W2336691688 hasConcept C2777761686 @default.
- W2336691688 hasConcept C2778963024 @default.
- W2336691688 hasConcept C2780258809 @default.
- W2336691688 hasConcept C2780962732 @default.
- W2336691688 hasConcept C38180746 @default.
- W2336691688 hasConcept C526805850 @default.
- W2336691688 hasConcept C71924100 @default.
- W2336691688 hasConcept C90924648 @default.
- W2336691688 hasConceptScore W2336691688C121608353 @default.
- W2336691688 hasConceptScore W2336691688C126322002 @default.
- W2336691688 hasConceptScore W2336691688C143998085 @default.
- W2336691688 hasConceptScore W2336691688C144301174 @default.
- W2336691688 hasConceptScore W2336691688C2776694085 @default.
- W2336691688 hasConceptScore W2336691688C2777761686 @default.
- W2336691688 hasConceptScore W2336691688C2778963024 @default.
- W2336691688 hasConceptScore W2336691688C2780258809 @default.
- W2336691688 hasConceptScore W2336691688C2780962732 @default.
- W2336691688 hasConceptScore W2336691688C38180746 @default.
- W2336691688 hasConceptScore W2336691688C526805850 @default.
- W2336691688 hasConceptScore W2336691688C71924100 @default.
- W2336691688 hasConceptScore W2336691688C90924648 @default.
- W2336691688 hasLocation W23366916881 @default.
- W2336691688 hasOpenAccess W2336691688 @default.
- W2336691688 hasPrimaryLocation W23366916881 @default.
- W2336691688 isParatext "false" @default.
- W2336691688 isRetracted "false" @default.
- W2336691688 magId "2336691688" @default.
- W2336691688 workType "article" @default.